芳基亚硝基化合物1-3容易与溴代丙二酸二甲酯反应,生成相应的N-芳基-C,C-二甲氧基羰基亚硝基(4-6)。用乙炔化合物(乙炔二羧酸二甲酯,2-丁酸甲酯或苯丙丙酸乙酯)处理C,C-二甲氧基羰基-N-(1-萘基)硝基(4)导致1,3-偶极环加成反应提供相应的1 H-苯[ g ]二氢吲哚(7a-c)。以类似的方式,硝酮5和6与乙炔化合物的反应得到相应的二氢吲哚9a-c和11a-c与4-恶唑啉13a-c和14a-c一起。
[EN] SYNTHESIS OF TRIAZOLOPYRIMIDINE COMPOUNDS<br/>[FR] SYNTHÈSE DE COMPOSÉS DE TRIAZOLOPYRIMIDINE
申请人:LEK PHARMACEUTICALS
公开号:WO2013060837A1
公开(公告)日:2013-05-02
The present invention relates to the field of organic synthesis and describes the synthesis of specific triazolopyrimidine compounds and intermediates thereof as well as related derivatives.
本发明涉及有机合成领域,描述了特定三唑吡咯啉化合物及其中间体的合成,以及相关衍生物。
[EN] INHIBITION OF OLIG2 ACTIVITY<br/>[FR] INHIBITION DE L'ACTIVITÉ D'OLIG2
申请人:CURTANA PHARMACEUTICALS INC
公开号:WO2018039621A1
公开(公告)日:2018-03-01
Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of Olig2. Also described herein are methods of using such Olig2 inhibitors, alone and in combination with other compounds, for treating cancer and other diseases. In particular the Olig2 inhibitors may be used to treat glioblastoma.
A Lewis Acid Catalyzed Annulation to 2,1-Benzisoxazoles
作者:Kate D. Otley、Jonathan A. Ellman
DOI:10.1021/jo5015432
日期:2014.9.5
We report here a new, atom economical annulation to 2,1-benzisoxazole scaffolds via the BF3·Et2O-catalyzed reaction of glyoxylate esters and nitrosoarenes. The developed method represents a convergent route to this compound class from previously unexplored inputs and provides a range of 2,1-benzisoxazoles in moderate to high yields under convenient conditions. Along with exploration of substrate scope
我们在这里报告了一种新的、通过乙醛酸酯和亚硝基芳烃的 BF 3 ·Et 2 O 催化反应形成 2,1-苯并异恶唑支架的原子经济环化。所开发的方法代表了从以前未探索的输入中合成此类化合物的收敛途径,并在方便的条件下以中等到高产率提供了一系列 2,1-苯并异恶唑。除了底物范围的探索之外,通过18 O 标记和反应中间体的合成进行的初步机理研究为乙醛酸盐以高 O 选择性向亚硝基苯进行不寻常的翻转加成,随后进行新型弗里德尔-克来福特环化提供了证据。
Piperazines as P2X7 antagonists
申请人:Betschmann Patrick
公开号:US20080076924A1
公开(公告)日:2008-03-27
Novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, metabolites thereof, isomers thereof, enantiomers thereof or prodrugs thereof of Formula (I)
wherein the substituents are as defined herein, which are useful as therapeutic agents.